These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 6264844)

  • 1. In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidime.
    Verbist L; Verhaegen J
    Antimicrob Agents Chemother; 1981 Mar; 19(3):402-6. PubMed ID: 6264844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of N-formimidoyl-thienamycin in comparison to that of moxalactam and cefotaxime against gentamicin-resistant gram-negative bacteria.
    Pusztai-Markos Z; Pranada F
    Eur J Clin Microbiol; 1982 Feb; 1(1):49-51. PubMed ID: 6293811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro comparative activity of moxalactam, GR 20263, and N-formimidoyl thienamycin to other beta-lactam antibiotics and tobramycin against enterobacteriaceae and staphylococci.
    Cynamon MH; Granato PA
    Chemotherapy; 1982; 28(3):204-8. PubMed ID: 6212205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of gram-positive cocci to various antibiotics, including cefotaxime, moxalactam, and N-formimidoyl thienamycin.
    Cherubin CE; Corrado ML; Sierra MF; Gombert ME; Shulman M
    Antimicrob Agents Chemother; 1981 Oct; 20(4):553-5. PubMed ID: 6282200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibacterial activity of N-formimidoyl thienamycin in comparison with cefotaxime, lamoxactam, cefoperazone, piperacillin gentamicin.
    Braveny I; Machka K; Elsser R
    Infection; 1982 Jan; 10(1):45-9. PubMed ID: 6279523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of inoculum size on activity of cefoperazone, cefotaxime, moxalactam, piperacillin, and N-formimidoyl thienamycin (MK0787) against Pseudomonas aeruginosa.
    Corrado ML; Landesman SH; Cherubin CE
    Antimicrob Agents Chemother; 1980 Dec; 18(6):893-6. PubMed ID: 6263178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative activity of N-formimidoyl thienamycin with third generation cephalosporins and ureido penicillins against multiple resistant Serratia marcescens.
    Miller MA; LeFrock JL; Vercler MJ
    Microbiol Immunol; 1981; 25(11):1119-27. PubMed ID: 6276701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance.
    Brown JE; Del Bene VE; Collins CD
    Antimicrob Agents Chemother; 1981 Feb; 19(2):248-52. PubMed ID: 6214986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activities of N-formimidoyl thienamycin and moxalactam against nonfermentative aerobic gram-negative rods.
    O'Donnell ED; Freimer EH; Gilardi GL; Raeder R
    Antimicrob Agents Chemother; 1982 Apr; 21(4):673-5. PubMed ID: 6211143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of N-formimidoyl thienamycin (MK0787), a crystalline derivative of thienamycin.
    Horadam VW; Smilack JD; Montgomery CL; Werringloer J
    Antimicrob Agents Chemother; 1980 Oct; 18(4):557-61. PubMed ID: 6934707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-Formimidoyl thienamycin (MK0787): in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
    Hanslo D; King A; Shannon K; Warren C; Phillips I
    J Antimicrob Chemother; 1981 Jun; 7(6):607-17. PubMed ID: 6265426
    [No Abstract]   [Full Text] [Related]  

  • 12. A comparison of the antibacterial activities of N-formimidoyl thienamycin (MK0787) with those of other recently developed beta-lactam derivatives.
    Cullmann W; Opferkuch W; Stieglitz M; Werkmeister U
    Antimicrob Agents Chemother; 1982 Aug; 22(2):302-7. PubMed ID: 6821459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of N-formimidoyl thienamycin and cephalosporins against isolates from nosocomially acquired bacteremia.
    Gutiérrez-Núñez J; Harrington PT; Ramirez-Ronda CH
    Antimicrob Agents Chemother; 1982 Mar; 21(3):509-12. PubMed ID: 6954876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superior activity of N-formimidoyl thienamycin against gentamicin-resistant Pseudomonas aeruginosa.
    Michael PR; Alford RH; McGee ZA
    Antimicrob Agents Chemother; 1981 Nov; 20(5):702-4. PubMed ID: 6798926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-formimidoyl thienamycin (MK0787): in vitro study.
    Shadomy S; May RS
    Antimicrob Agents Chemother; 1981 Jan; 19(1):201-4. PubMed ID: 6941741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative activities of 13 beta-lactam antibiotics.
    Muytjens HL; van der Ros-van de Repe J
    Antimicrob Agents Chemother; 1982 Jun; 21(6):925-34. PubMed ID: 7114839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefoperazone against carbenicillin-resistant isolates of Pseudomonas aeruginosa: comparison with other newer cephalosporins and N-formimidoyl thienamycin.
    Chau PY; Ling J; Ng WS
    J Antimicrob Chemother; 1983 Oct; 12(4):337-45. PubMed ID: 6417100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro susceptibilities of anaerobic bacteria to cefmenoxime, cefotetan, and N-formimidoyl thienamycin.
    Owens WE; Finegold SM
    Antimicrob Agents Chemother; 1983 Apr; 23(4):626-9. PubMed ID: 6305265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftazidime: in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
    Phillips I; Warren C; Shannon K; King A; Hanslo D
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():23-31. PubMed ID: 19802967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative.
    Eickhoff TC; Ehret J
    Antimicrob Agents Chemother; 1981 Mar; 19(3):435-42. PubMed ID: 6264845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.